Key Details
Price
$69.63Annual Revenue
$3.70 BAnnual EPS
$2.65Annual ROE
12.50%Beta
0.45Events Calendar
Next earnings date:
Feb 13, 2025Recent quarterly earnings:
Oct 29, 2024Recent annual earnings:
Feb 13, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Sept 01, 2000Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Levi & Korsinsky has informed investors that it is starting an investigation into Incyte Corporation (NASDAQ:INCY) for potential breaches of federal securities laws. On November 18, 2024, Incyte announced that it would stop enrolling participants in the Phase 2 trial of its drug INCB000262 for chronic spontaneous urticaria (CSU) because of some concerning preclinical toxicology results.
Levi & Korsinsky has informed investors that it is starting an investigation into Incyte Corporation (NASDAQ:INCY) for potential breaches of federal securities laws. On November 18, 2024, Incyte announced that it would stop enrolling participants in the Phase 2 study of its drug INCB000262 for chronic spontaneous urticaria (CSU) because of some concerning preclinical toxicology results.
Levi & Korsinsky has informed investors that it is starting an investigation into Incyte Corporation (NASDAQ:INCY) for potential breaches of federal securities laws. On November 18, 2024, Incyte announced that it would stop enrolling participants in the Phase 2 trial of its drug INCB000262 for chronic spontaneous urticaria (CSU) because of some concerning preclinical toxicology results.
Levi & Korsinsky has informed investors that it is starting an investigation into Incyte Corporation (NASDAQ:INCY) for potential breaches of federal securities laws. On November 18, 2024, Incyte announced that it would stop enrolling participants in the Phase 2 trial of its drug INCB000262 for chronic spontaneous urticaria (CSU) because of some concerning preclinical toxicology results.
INCY's phase III trial, which looked at retifanlimab used with platinum-based chemotherapy for treating metastatic non-small cell lung cancer, achieved its main and additional goals.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte has reported encouraging outcomes from a Phase 3 study that tested Retifanlimab (Zynyz) alongside platinum-based chemotherapy for non-small cell lung cancer (NSCLC).
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte has announced inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4).
Levi & Korsinsky has informed investors that it is starting an investigation into Incyte Corporation (NASDAQ:INCY) for potential breaches of federal securities laws. On November 18, 2024, Incyte announced that it would stop enrolling participants in the Phase 2 trial of its drug INCB000262 for chronic spontaneous urticaria (CSU) because of some concerning preclinical toxicology results.
Levi & Korsinsky has informed investors that it is starting an investigation into Incyte Corporation (NASDAQ:INCY) for potential breaches of federal securities laws. On November 18, 2024, Incyte announced that it would stop enrolling participants in the Phase 2 trial of its drug INCB000262 for chronic spontaneous urticaria (CSU) because of some concerning preclinical toxicology results.
Levi & Korsinsky has informed investors that it is starting an investigation into Incyte Corporation (NASDAQ:INCY) for potential breaches of federal securities laws. This comes after Incyte announced on November 18, 2024, that it would stop enrolling participants in the Phase 2 trial of its drug INCB000262 for chronic spontaneous urticaria (CSU) because of some concerning preclinical toxicology results.
FAQ
- What is the primary business of Incyte?
- What is the ticker symbol for Incyte?
- Does Incyte pay dividends?
- What sector is Incyte in?
- What industry is Incyte in?
- What country is Incyte based in?
- When did Incyte go public?
- Is Incyte in the S&P 500?
- Is Incyte in the NASDAQ 100?
- Is Incyte in the Dow Jones?
- When was Incyte's last earnings report?
- When does Incyte report earnings?
- Should I buy Incyte stock now?